Vergelijking
Retatrutide vs. VK2735
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
2381089-83-2
geen gegevens
Molecuulmassa
4731.6 g/mol
geen gegevens
Halfwaardetijd
144 h
geen gegevens
Sequentie
Y-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSgeen gegevens
Werkingsmechanisme
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
VK2735
VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
5
1
waarvan bij mensen
4
1
Geregistreerde effecten
4
2
Openstaande tegenstrijdigheden
1
0
Gedocumenteerde bijwerkingen
2
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Retatrutide and VK2735?
- Retatrutide is classified as "Metabool", while VK2735 is classified as "Metabool". Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Retatrutide or VK2735?
- The highest available evidence level is "Humane RCT" for Retatrutide and "Humane RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Retatrutide and VK2735 in Germany and the United States?
- Duitsland: Retatrutide — Niet goedgekeurd, VK2735 — Niet goedgekeurd. Verenigde Staten: Retatrutide — Niet goedgekeurd, VK2735 — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.